Interestingly, the MCF7 derivative strains with acquired resistance to tamoxifen (Tam-R) or oestrogen deprivation (ED-R)32 retained high sensitivity to TLK2 inhibition (Fig. 4a), suggesting the potential of TLK2 inhibition in managing these acquired resistant breast tumours. The gene discussed is TLK2; the disease is breast neoplasm.